GlaxoSmithKline Divests Brands in Australia for $271 Million - - BioPharm International

ADVERTISEMENT

GlaxoSmithKline Divests Brands in Australia for $271 Million



GlaxoSmithKline (GSK) is selling the majority of its ‘classic brands’ in Australia to Aspen Global for approximately £172 million ($271.1 million) in cash. The move is part of GSK’s ongoing strategy to simplify business by selling low-growth and noncore assets in order to focus on priority brands, products and pipeline opportunities.

The divested brands comprise 25 products that have been genericised or that are no longer promoted by the company, including the herpes medicine Valtrex, beta-lactam antibiotic Timentin, and the epilepsy and bipolar drug Lamictal. The brands generated around £83 million ($130.8 million) in total sales in 2011 and £31 million ($48.9 million) in the first half of 2012. In a statement, GSK explained that revenues for the products had gradually declined in recent years because of “local market price reductions and generic competition”.

However, Aspen added in a statement, “Whilst the Products received little promotional focus from GSK, Aspen is confident that it will be able to leverage its proven ability to reinvigorate older brands and the Products’ considerable brand equity in order to enhance the value of the portfolio.”

The divestment is expected to be completed in the fourth quarter of this year, subject to regulatory approvals.

Earlier this year, GSK divested several over-the-counter brands in select territories to Aspen for approximately $264.7 million.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here